Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R10 - February 18, 2025

Date Posted: April 25, 2025

This Billing and Coding Article has been revised under contractor numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, and NMI), and 01312 (NV).

Effective Date: February 18, 2025

Summary of Changes:

Under Article Text revised subheading Additional Test-specific Indications, Limitations and Instructions (2) added "Non-small cell lung cancer (NSCLC) (Natera)." This revision is due to covered test that has successfully completed a TA and is effective for 2/18/2025.

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.

Last Updated Apr 24 , 2025